KnowTheStock
Log inCreate free account

AbbVie Inc.

ABBV
S&P 500Pharmaceutical Preparations · NYSE
$254.31last close · market cap 450.38 Billion
Compare with…
43.3SCORE / 100
Our verdictSELLModerate Growth and Stable, Stock Price Very HighQtr Ending 2026-06-30

Why Sell

Income statement is strong; cash flow is moderate; balance sheet is weak.

Next earnings: 2026-10-30 (BMO), EPS Forecast: $3.76

What is strong
  • Revenue Growth is 10.39%
  • Operating Income Growth is 53.81%
  • Net Income Growth is 68.18%
  • Earnings Per Share (EPS) Growth is 68.57%
  • Capital Expenditure is Low
  • Net Increase in Cash is Positive
What to watch
  • Net Margin is 9.75%
  • Current Asset to Current Liability Ratio is 0.81
  • Debt Ratio is 0.56
  • Current Debt to Net Income Ratio is 2.32
  • Total Debt to Total Assets Ratio is 0.52
  • Cash from Operations Growth is 1.16%
  • Investment Risk is High

What changed

Score by quarter

Downgraded from Hold to Sell in the Jun 2023 quarter: 54.0 → 54.9 (+0.8). This quarter: +4.6.

3040506070Sep 2022Jun 2026

What the score is made of

Income statement60.3 +9.2
Balance sheet7.8 -0.0
Cash flow50.3 -2.6

Change vs previous quarter.

Key numbers · latest quarter

Revenue (TTM)64.39 Billion10.39 % growth
EPS3.5468.57 % growth
Profit margin9.75 %Profit per $1 of sales
P-E ratio—Not available
Market cap450.38 BillionShares × price
Debt-equity ratio-11.93Leverage
Dividend6.74Per share, annual
Next earnings2026-10-30BMO · EPS forecast $3.76
Better viewed in landscape mode.
Unless specified, all values are in USD Millions. Data extracted from SEC Filing and are subject to processing and input errors.

About AbbVie Inc.

AbbVie Inc. is a pharmaceutical company headquartered in North Chicago, Illinois. It is ranked 6th on the list of largest biomedical companies by revenue. Their primary product is Humira (adalimumab) ($21 billion in 2022 revenues, 37% of total), administered via injection. It is approved to treat autoimmune diseases including rheumatoid arthritis, Crohns disease, plaque psoriasis, and ulcerative colitis.

CEO
Richard Gonzalez
Employees
50,000
Sector
Professional, Scientific, and Technical Services
Exchange
NYSE
abbvie.com

Similar stocks

Loading…